Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| BTK (Bruton tyrosine kinase) Target is wild-type; resistance mutations arise on treatment | 100% | pathway dependence (BCR signalling), not a mutation | |
| CD52 IHC survey of 294 haematologic neoplasms: vast majority of CLL/SLL positive (Rodig 2006, doi:10.1158/1078-0432.CCR-06-1275) | 100% | Surface CD52 on essentially all B and T lymphocytes (Campath label); CLL cells uniformly CD52-positive | FDA |
| CD19 | >95% | Surface expression | Wikipedia |
| BCL-2 | >90% | BCL-2 overexpression | Wikipedia |
| CD20 | >90% | Dim surface expression | Wikipedia |
| ROR1 | >90% | Surface expression | Wikipedia |
| PI3K delta (PIK3CD) | all% | PI3K delta is the B-cell form of the enzyme, present in essentially every B-cell malignancy; drugs are chosen by disease, not by a test | cancer.gov |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
3 cell lines, 1 mouse models and 1 repositories are listed for this cancer. See them →